Bromopride (INN) is a dopamine antagonist with prokinetic properties widely used as an antiemetic, closely related to metoclopramide. It is not available in the United States.
Bromopride appears to be safe and effective for use in pregnancy.[1]
Bromopride is generally well tolerated; the most common adverse effects of its use are somnolence and fatigue. Bromopride may rarely cause extrapyramidal symptoms and, as metoclopramide, may increase prolactin levels.[2]
Chemistry
Bromopride is a substituted benzamide, closely related to metoclopramide.[3] It is identical to metoclopramide except for the presence of a bromine atom where metoclopramide has a chlorine substituent.
Availability
Bromopride is not available in the United States or the United Kingdom. It is marketed in Brazil by Sanofi-Synthélabo under the trade name Digesan and as a generic drug.
References
^ Araújo JR (1981). "Evaluation of bromopride in nausea and vomiting of pregnancy" (in Portuguese). J Bras Ginecol91 (4): 283–5.
^ Bula do Profissional de Saúde: Bromoprida (Portuguese). Bulário Eletrônico da Anvisa. Brazilian National Health Surveillance Agency (April 11 2006). Retrieved on 2007-07-23.
^ Brodie RR, Chasseaud LF, Darragh A, Lambe RF, Rooney L, Taylor T (1986). "Pharmacokinetics and bioavailability of the anti-emetic agent bromopride". Biopharm Drug Dispos7 (3): 215–22. doi:10.1002/bdd.2510070302. PMID 3730521.
v•d•e
Drugs for functional gastrointestinal disorders (A03)
Top